All HIV articles – Page 3
-
NewsCalibr announces license agreement with Gilead to develop long-acting HIV antiviral agent
Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical care
-
NewsResearchers ID opportunities to improve future HIV vaccine candidates
An effective HIV vaccine may need to prompt strong responses from immune cells called CD8+ T cells to protect people from acquiring HIV, according to a new study.
-
NewsMpox vaccine triggers equally strong immune response in smaller doses
Delivering the two-dose mpox vaccine in smaller than the usual FDA-approved doses produced a detectable immune response. This also occurred regardless of whether people were living with or without HIV.
-
NewsScientists find new, better way to develop vaccines
Researchers have developed a new system to display epitopes in mammal cells for immunization studies and believe that this method can help scientists greatly in immunization efforts.
-
News40 years after the discovery of HIV, research raises hopes of remission
The conference ’40 years of HIV science’ was an opportunity to look back at the major advances that are raising hopes of remission and a cure for HIV.
-
NewsHIV drug could prevent coronaviruses, study finds
New research has shown how an HIV drug could stop many coronavirus diseases, including the SARS-CoV-2 variants, when given to infected cells at the right concentration.
-
NewsVery early antiretroviral therapy within hours of birth could suppress HIV in newborns
A study of more than 50 babies through 2 years old supports evidence that giving antiretroviral therapy (ART) to newborns with HIV within the first days of life can safely suppress amounts of HIV in the blood to undetectable levels.
-
NewsU/EEA: HIV diagnoses rise for the first time in a decade
The increase in 2022 can be attributed to several factors including restoring surveillance activities, scale-up and introduction of novel testing strategies in many countries, migration patterns, lifting of COVID-19 restrictions and arrival of refugees.
-
Long ReadsGender-specific approaches to HIV prevention: addressing the needs of women and girls
With nearly 25 million deaths and an estimated 33.2 million people (including 15.4 million women) living with the virus globally, HIV/AIDS is on the brink of becoming the most devastating pandemic the world has ever seen.
-
NewsHIV: Thwarting a protein in the hope of a better quality of life
The sustained activation of the body’s immune system for people living with HIV leads to chronic inflammation that can cause associated complications such as cardiovascular diseases, osteoporosis or neurocognitive decline.
-
NewsStudy uncovers mediators of persistent HIV viremia
Researchers examining people with non-suppressible HIV viremia (NSV) despite receiving antiretroviral therapy (ART) have found large reservoirs of proviruses inserted into transcriptionally active regions of immune cell genomes.
-
NewsCOVID-19 compromised U.S. gains in controlling HIV and worsened health disparities
The COVID-19 pandemic slowed previous gains made in controlling HIV blood levels and worsened health disparities, according to researchers leading the largest U.S. evaluation of the impact of the public health crisis on people with HIV.
-
NewsResearchers invent single, rapid test for both HIV and TB
Scientists have developed a new and rapid test that can detect both HIV and tuberculosis at the same time with just a small amount of blood.
-
NewsVaginal film that dissolves in 30 days may offer HIV prevention method for women
A vaginal film designed to slowly dissolve over the course of 30 days is being put to the test for the first time in a study that aims to determine its feasibility and acceptability as a potential HIV prevention method for women.
-
NewsTB vaccine discovery paves path to end no. 1 killer of people living with HIV
Scientists have discovered a tuberculosis (TB) vaccination strategy that could prevent the leading cause of death among people worldwide living with HIV.
-
NewsClinical trial of HIV vaccine begins in United States and South Africa
A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa. The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific immune response in people. Source: NIAID Transmission electron micrograph ...
-
News’Dormant’ HIV produces RNA and proteins during anti-retroviral therapy
Two independent groups of researchers report that a subset of ‘dormant’ HIV-infected cells spontaneously produce HIV RNA and proteins that may impact patients’ HIV-specific immune responses.
-
NewsTwo autopsies reveal secrets of HIV reservoirs
A research team shows for the first time that HIV reservoirs are concentrated in the spleen and lymph nodes, and that they can travel throughout the body.
-
NewsBlood cancer drug shows promise in killing ‘silent’ HIV cells
An existing blood cancer drug has shown promise in killing ‘silent’ HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease.
-
NewsTests of new antifungal therapy for fungal meningitis are successful
Researchers have successfully tested a new oral formulation of the antifungal medication amphotericin among people who had HIV and cryptococcal meningitis - a common fungal infection around the brain.
